Group 1: Earnings Performance - Envista reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.24 per share, and up from $0.11 per share a year ago, representing an earnings surprise of +8.33% [1] - The company has surpassed consensus EPS estimates for four consecutive quarters [2] - Envista's revenues for the quarter ended June 2025 were $682.1 million, surpassing the Zacks Consensus Estimate by 6.34%, and up from $633.1 million year-over-year [2] Group 2: Stock Performance and Outlook - Envista shares have increased approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 8.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.25 on revenues of $621.65 million, and for the current fiscal year, it is $1.04 on revenues of $2.55 billion [7] Group 3: Industry Context - The Medical - Products industry, to which Envista belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Envista's stock performance [5][6]

Financial Data and Key Metrics Changes - Q2 2025 revenue was $682 million, with core sales increasing by 5.6% year-over-year, aided by customer buying ahead of expected price increases [8][16] - Adjusted EBITDA margin was 12.4%, up 240 basis points from the previous year, supported by G&A productivity improvements [9][16] - Adjusted EPS for Q2 was $0.26, an increase of $0.15 compared to the same quarter last year [16][18] - Free cash flow for Q2 was $76 million, down from the previous year due to higher working capital [26] Business Line Data and Key Metrics Changes - Equipment and consumables revenue grew approximately 7%, while specialty products increased just shy of 5% [9][22] - Specialty Products and Technology segment saw core revenue growth of 7.2%, with adjusted operating margin improving to 13.5% [22] - Equipment and Consumables segment reported a 7.3% increase in core sales, with diagnostics showing mid-single-digit growth in North America [24] Market Data and Key Metrics Changes - Double-digit growth was observed in Latin America, Indo-Pacific, and Middle East and Africa regions [14] - The dental market remains stable, with no significant improvement or deterioration expected in the second half of 2025 [28][32] Company Strategy and Development Direction - The company is focused on a value creation plan that includes accessing untapped growth in core markets, new product innovation, and strategic acquisitions [11][12] - Plans to expand manufacturing in China to support local demand, with a new site in Suzhou [14][15] - Continued investment in R&D, with a 14% increase in the first half of 2025, leading to several new product launches [13] Management's Comments on Operating Environment and Future Outlook - Management noted that macroeconomic conditions have improved slightly, with low unemployment and rising consumer confidence [36][39] - The company anticipates a stable dental market and expects to offset tariff impacts through supply chain actions and cost reductions [29][30] - Future guidance was updated to reflect core revenue growth of 3% to 4% and adjusted EPS of $1.5 to $1.15 [10][27] Other Important Information - The company repurchased $82 million worth of shares in Q2, continuing a $250 million two-year repurchase authorization [27] - The adjusted tax rate for the year is now forecasted at 33%, improved due to strong U.S. profits [30] Q&A Session Summary Question: Was the strength seen across the portfolio surprising? - Management noted that Q2 macro conditions were incrementally better than Q1, with strong growth in orthodontics and consumables [36][38] Question: What drove the outsized growth in brackets and wires? - Increased investment in sales and marketing and a potential shift from clear aligners to brackets and wires contributed to growth [42] Question: How is the China market performing ahead of VBP? - The brackets and wires business in China was down 20-30% year-over-year in the first half, but robust growth is expected in Q4 post-VBP [51] Question: What is the outlook for Spark's profitability? - The company expects Spark to turn EBIT positive in the second half of 2025, with consistent unit cost reductions [59] Question: How are dental practices responding to price increases? - Price increases have been modest and well-received, with a delay in equipment purchases noted across the market [90][91] Question: What is the impact of tariffs on margins? - Tariff costs in Q2 diluted margins by approximately 60 basis points, with expectations of $15 million to $20 million in tariff costs in the second half [80]

Q2 2025 Performance - Core sales growth reached 5.6%[16], with adjusted EBITDA margin at 12.4%[16] and adjusted EPS at $0.26, a 136% year-on-year increase[16] - Specialty Products & Technologies (SP&T) experienced a core sales growth of 4.7%[16], while Equipment & Consumables (E&C) saw a core sales growth of 7.3%[16] - Free cash flow was $76 million[28] H1 2025 Performance - Core sales growth was 2.9%[16], with adjusted EBITDA margin at 12.6%[16] and adjusted EPS at $0.50, a 35% year-on-year increase[16] FY2025 Updated Guidance - Core sales growth guidance raised from 1-3% to 3-4%[16] - EPS guidance increased from $0.95 - $1.05 to $1.05 - $1.15[16] - Adjusted EBITDA margin guidance maintained at approximately 14%[16] Revenue and Growth Analysis - Q2 2025 revenue was $682.1 million, an increase of $49.0 million compared to $633.1 million in Q2 2024[25] - Reported revenue growth was 7.7%, with core growth contributing 5.6%[29] Adjusted EBITDA Analysis - Adjusted EBITDA for Q2 2025 was $84.3 million, compared to $63.0 million in Q2 2024, representing a 34% increase[27, 25] - Adjusted EBITDA margin increased by 240 bps to 12.4%[27, 25]

Envista Reports Second Quarter 2025 Results Exhibit 99.1 BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended June 27, 2025. "Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter," said Paul Keel, CEO. "This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year- over-year profitability. Based on the fir ...

Core Viewpoint - Envista (NVST) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in stock price movements [4]. Company Performance and Outlook - The recent upgrade for Envista suggests an improvement in its underlying business, which could lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Envista is expected to earn $1.04 per share, with a 6% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Envista's upgrade places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Envista Holdings Corporation (NVST) has reached a significant support level and is considered a potential investment opportunity due to a recent "golden cross" technical pattern, indicating a bullish breakout [1]. Technical Analysis - NVST's 50-day simple moving average has recently crossed above its 200-day moving average, forming a "golden cross," which is a bullish signal in technical analysis [1]. - A successful golden cross event consists of three stages: the stock price bottoms out, the shorter moving average crosses above the longer moving average, and the stock maintains upward momentum [2]. Performance Metrics - Over the past four weeks, NVST has gained 5.2%, and it currently holds a 1 (Strong Buy) rating on the Zacks Rank, suggesting potential for further breakout [3]. - Earnings expectations for NVST are positive, with one upward revision in estimates over the past 60 days, indicating confidence in the stock's bullish trend [3]. Investment Outlook - Given the key technical level and positive earnings estimate revisions, NVST is positioned for potential gains in the near future [5].

Company Overview - Envista (NVST) is expected to report a year-over-year increase in earnings, with a consensus estimate of $0.24 per share, reflecting a change of +118.2% [3] - Revenues are anticipated to be $641.45 million, which is a 1.3% increase from the previous year [3] Earnings Expectations - The earnings report is scheduled for July 31, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Most Accurate Estimate for Envista is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.65%, suggesting a bearish outlook from analysts [12] - Despite the negative Earnings ESP, Envista holds a Zacks Rank of 2, complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Envista exceeded the expected earnings of $0.20 per share, achieving $0.24, which was a surprise of +20.00% [13] - Over the past four quarters, Envista has beaten consensus EPS estimates three times [14] Industry Context - InMode (INMD), another player in the Zacks Medical - Products industry, is expected to post earnings of $0.43 per share, indicating a year-over-year change of +26.5% [18] - InMode's revenues are projected to be $95.5 million, up 10.5% from the previous year [18] - The consensus EPS estimate for InMode has been revised down by 9.8% over the last 30 days, and it currently has an Earnings ESP of 0% with a Zacks Rank of 5 [19]

Core Viewpoint - Investors in the Medical - Products sector should consider Envista (NVST) and Abbott (ABT) for potential value opportunities, with NVST currently presenting a more attractive option based on various valuation metrics and earnings outlook [1][3][7]. Valuation Metrics - NVST has a forward P/E ratio of 18.81, while ABT has a higher forward P/E of 24.16, indicating that NVST may be undervalued compared to ABT [5]. - The PEG ratio for NVST is 1.23, suggesting a better valuation relative to its expected earnings growth compared to ABT's PEG ratio of 2.36 [5]. - NVST's P/B ratio stands at 1.09, significantly lower than ABT's P/B ratio of 4.41, further indicating NVST's relative undervaluation [6]. Earnings Estimate Revisions - NVST has experienced stronger estimate revision activity, which is a positive indicator for its earnings outlook compared to ABT [3][7]. - The Zacks Rank system rates NVST as 2 (Buy) and ABT as 3 (Hold), reflecting a more favorable earnings estimate revision trend for NVST [3]. Value Grades - NVST has been assigned a Value grade of B, while ABT has a Value grade of C, highlighting NVST's superior valuation metrics [6].

Core Viewpoint - Envista Holdings Corporation will report its financial results for the second quarter of 2025 on July 31, 2025, with a conference call scheduled for 2:00 PM PT to discuss these results [1]. Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [4]. - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [4]. - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [4]. Conference Call Details - The conference call will be accessible via a dial-in number, with a U.S. number of 1-800-836-8184 and an international number of +1 646-357-8785, starting a few minutes before the call [2]. - A replay of the webcast will be available shortly after the presentation concludes, and related materials will be posted on the "Investors" section of Envista's website [3].

Core Viewpoint - The comparison between Envista (NVST) and Abbott (ABT) indicates that NVST may offer better value for investors based on various financial metrics and rankings [1][3]. Valuation Metrics - Envista has a forward P/E ratio of 18.81, while Abbott's forward P/E is significantly higher at 26.65 [5]. - The PEG ratio for Envista is 1.23, indicating a more favorable valuation in relation to its expected earnings growth compared to Abbott's PEG ratio of 2.61 [5]. - Envista's P/B ratio stands at 1.08, contrasting with Abbott's P/B ratio of 4.87, further suggesting that Envista is undervalued relative to its book value [6]. Zacks Rank and Style Scores - Envista holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Abbott has a Zacks Rank of 3 (Hold) [3]. - In the Value category, Envista receives a grade of B, whereas Abbott is graded C, highlighting Envista's stronger position for value investors [6].